Unknown

Dataset Information

0

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector.


ABSTRACT: BACKGROUND:The development of an effective human immunodeficiency virus (HIV) vaccine is a high global priority. Here, we report the safety, tolerability, and immunogenicity of a replication-defective recombinant adenovirus serotype 5 (rAd5) vector HIV-1 candidate vaccine. METHODS:The vaccine is a mixture of 4 rAd5 vectors that express HIV-1 subtype B Gag-Pol fusion protein and envelope (Env) from subtypes A, B, and C. Healthy, uninfected adults were randomized to receive 1 intramuscular injection of placebo (n=6) or vaccine at dose levels of 10(9) (n=10), 10(10) (n=10), or 10(11) (n=10) particle units and were followed for 24 weeks to assess immunogenicity and safety. RESULTS:The vaccine was well tolerated but was associated with more reactogenicity at the highest dose. At week 4, vaccine antigen-specific T cell responses were detected in 28 (93.3%) and 18 (60%) of 30 vaccine recipients for CD4(+) and CD8(+) T cells, respectively, by intracellular cytokine staining assay and in 22 (73%) of 30 vaccine recipients by enzyme-linked immunospot assay. Env-specific antibody responses were detected in 15 (50%) of 30 vaccine recipients by enzyme-linked immunosorbant assay and in 28 (93.3%) of 30 vaccine recipients by immunoprecipitation followed by Western blotting. No neutralizing antibody was detected. CONCLUSIONS:A single injection induced HIV-1 antigen-specific CD4(+) T cell, CD8(+) T cell, and antibody responses in the majority of vaccine recipients. This multiclade rAd5 HIV-1 vaccine is now being evaluated in combination with a multiclade HIV-1 DNA plasmid vaccine.

SUBMITTER: Catanzaro AT 

PROVIDER: S-EPMC2428071 | biostudies-literature | 2006 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector.

Catanzaro Andrew T AT   Koup Richard A RA   Roederer Mario M   Bailer Robert T RT   Enama Mary E ME   Moodie Zoe Z   Gu Lin L   Martin Julie E JE   Novik Laura L   Chakrabarti Bimal K BK   Butman Bryan T BT   Gall Jason G D JG   King C Richter CR   Andrews Charla A CA   Sheets Rebecca R   Gomez Phillip L PL   Mascola John R JR   Nabel Gary J GJ   Graham Barney S BS  

The Journal of infectious diseases 20061108 12


<h4>Background</h4>The development of an effective human immunodeficiency virus (HIV) vaccine is a high global priority. Here, we report the safety, tolerability, and immunogenicity of a replication-defective recombinant adenovirus serotype 5 (rAd5) vector HIV-1 candidate vaccine.<h4>Methods</h4>The vaccine is a mixture of 4 rAd5 vectors that express HIV-1 subtype B Gag-Pol fusion protein and envelope (Env) from subtypes A, B, and C. Healthy, uninfected adults were randomized to receive 1 intram  ...[more]

Similar Datasets

| S-EPMC7248191 | biostudies-literature
| S-EPMC6934588 | biostudies-literature
2020-10-01 | GSE158835 | GEO
| S-EPMC114747 | biostudies-literature
| S-EPMC7610941 | biostudies-literature
| S-EPMC2943475 | biostudies-literature
| S-EPMC2428069 | biostudies-literature
| S-EPMC112946 | biostudies-literature
| PRJNA666676 | ENA
| S-EPMC8062434 | biostudies-literature